latest news releases from the newsroom
Elecsys Corporation Begins Trading On the NASDAQ Stock Market
OLATHE, Kan., March 10, 2009 (GLOBE NEWSWIRE) -- Elecsys Corporation (Nasdaq:ESYS) announces that its stock will commence trading today on the NASDAQ Stock Market under the symbol ESYS. The Company had previously traded on the NYSE Alternext U.S. LLC (formerly AMEX) under the ticker symbol ASY.
Stimulus Focus On Smart Grids May Impact mPhase
LITTLE FALLS, N.J., March 10, 2009 (GLOBE NEWSWIRE) -- The most recent stimulus package has set aside $4.5 billion for smart grid technology advancements which may impact mPhase Technologies, Inc. (OTCBB:XDSL) due to their SmartBattery Technology. The Smart NanoBattery is currently being developed as part of the U.S. Army STTR program, and has the flexibility to function within a wide range of applications.
Lime Energy to Divest Energy Technology Division
ELK GROVE VILLAGE, Ill., March 10, 2009 (GLOBE NEWSWIRE) -- Lime Energy Co. (Nasdaq:LIME) announced today its intent to divest its energy technology division which is comprised of its proprietary line of eMAC HVAC and uMAC lighting controls. The company has engaged the investment banking firm William Blair & Company to assist with the divestiture.
CardinalCommerce and CyberSource Team Up to Offer Enhanced Support of Verified by Visa and MasterCard SecureCode Programs for Merchants
MENTOR, Ohio, March 10, 2009 (GLOBE NEWSWIRE) -- CardinalCommerce Corporation, the worldwide-leading payment brand enabler, today announced a new strategic partnership with CyberSource Corporation (Nasdaq:CYBS), a leading provider of electronic payment and risk management solutions. CardinalCommerce has integrated its Cardinal Centinel(r) Platform with CyberSource's payment management services to provide CyberSource merchants with continued, strengthened support for Verified by Visa (VbV) and MasterCard(r) SecureCode(tm) (MCSC).
EDAP TMS SA
EDAP Receives FDA Permission to Amend Ongoing Ablatherm-HIFU U.S. Clinical Study Protocol
LYON, France, March 10, 2009 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that the U.S. Food and Drug Administration (FDA) approved the following protocol amendments for the Company's ongoing U.S. clinical study of Ablatherm-HIFU (high intensity focused ultrasound) for the treatment of patients with localized prostate cancer: